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Abstract 
Background: There is uncertainty about the comparative safety and effi cacy of the fi xed-dose-
combination tablets tenofovir 300mg+emtricitabine 200mg (TDF/FTC); and abacavir 600mg+lamivudine 
300mg (ABC/3TC). Methods: We used random effects meta-analysis to compare 96 week data for ABC/
3TC and TDF/FTC randomised arms from the BICOMBO (n=333) and STEAL (n=357) treatment 
experienced and virologically suppressed switch studies. Endpoints included: virological failure (VF, 
repeat plasma HIV RNA >400 copies/mL); mean change to week 96 in CD4 and metabolic parameters; 
proportion with serious non-AIDS events (SNAEs, retrospectively collected in BICOMBO). We used exact 
statistics for relative difference in proportions (RD), and ANOVA for differences between means. 
Difference was for ABC/3TC minus TDF/FTC. Results: There was no signifi cant difference between arms 
in VF (RD% 0.7 95%CI -3.4, 4.8). Change from baseline in CD4 was of marginal signifi cance (ITT 0.16 
cells/mL 95%CI 0.0, 0.32). Mean change in HDL, LDL, total cholesterol triglycerides were signifi cantly 
greater in the ABC/3TC arm (p <0.01 for all), there was no difference in total cholesterol:HDL ratio (0.11 
95%CI -0.16, 0.29). There was a greater proportion of SNAEs in the ABC/3TC arm (relative difference 
3.8%, 95%CI 0.1, 7.6) primarily arising from the STEAL study. Conclusions: In a switch study setting ABC/
3TC based therapy was virologically non-inferior over 96 weeks to TDF/FTC based therapy. Lipid markers 
were generally elevated in the ABC/3TC arm. 
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Introduction
In 2004 fixed dose combination (FDC) tablets containing 
abacavir (ABC)+lamivudine (3TC) (Kivexa®) and tenofovir (TDF) + 
emtricitabine (FTC) (Truvada®) were licensed. The long term safety 
and efficacy profile of these drugs in once-daily, FDC formulations is 
not known. In recent years particular attention has been drawn to 
the effect of antiretroviral (ARV) therapies on the incidence of serious 
non-AIDS events (SNAEs), including cardiovascular disease (CVD), 
end-stage renal disease, liver failure and fractures.[1-3]Of particular 
interest is the effect of individual ARVs or ARV classes on these 
events. There has been some indication, though not consistent, of an 
association between ABC and CVD.[4-6] There are also some data to 
suggest TDF exposure may be associated with renal toxicity, at least 
during early exposure, and bone loss.[7-11]
Two very similar randomised clinical trials investigating the 
safety and efficacy of switching to ABC+3TC or TDF+FTC FDC 
combinations in ARV therapy experienced HIV infected stable 
and virologically suppressed populations were commenced in 
2005 in Spain (BICOMBO) and Australia (STEAL). [12,13] Both trials 
completed 96 week follow up in 2008. The availability of data from 
these trials provides an opportunity to investigate consistency and 
generalisability of study outcomes. 
Methods
Source data were extracted for the trials by the statisticians 
responsible for each trial. End points for each trial were analysed 
using a pre-specified analysis plan to ensure that all analyses were 
conducted in the same manner.  Analyses were conducted for data 
collected up to week 96. The primary endpoint was proportion with 
virological failure [VF] (repeat plasma HIV RNA >400 copies/mL; 
intention-to-treat, missing=failure [ITTM=F] analysis). Secondary 
endpoints were VF missing/switch =failure [ITTS=F], VF (per 
protocol [PP]), mean change from baseline to week 96 in CD4 (ITT 
last observation carried forward and PP), metabolic parameters (per 
protocol [PP]) and proportions with serious non-AIDS events (SNAE). 
In STEAL, SNAE endpoints were defined and collected in 
February 2006, after the study commenced but before the database 
was un-blinded and analysed in August, 2008 [13]. SNAE data were 
retrospectively collected in BICOMBO in 2009 by blinded review of 
clinical records by two site physicians for events as defined in the 
STEAL study. In brief SNAEs were defined as cardiovascular events 
(myocardial infarction, ischaemic stroke, peripheral vascular disease, 
cardiac revascularisation procedure), non-AIDS defining cancer, end-
stage liver disease, non-traumatic fractures of long torso-bones. 
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Abstract
Background:  There is uncertainty about the comparative safety and effi cacy of the fi xed-dose-combination tablets 
tenofovir 300mg+emtricitabine 200mg (TDF/FTC); and abacavir 600mg+lamivudine 300mg (ABC/3TC). 
Methods: We used random effects meta-analysis to compare 96 week data for ABC/3TC and TDF/FTC randomised 
arms from the BICOMBO (n=333) and STEAL (n=357) treatment experienced and virologically suppressed switch 
studies. Endpoints included: virological failure (VF, repeat plasma HIV RNA >400 copies/mL); mean change to week 
96 in CD4 and metabolic parameters; proportion with serious non-AIDS events (SNAEs, retrospectively collected in 
BICOMBO). We used exact statistics for relative difference in proportions (RD), and ANOVA for differences between 
means. Difference was for ABC/3TC minus TDF/FTC.
Results: There was no signifi cant difference between arms in VF (RD% 0.7 95%CI -3.4, 4.8). Change from 
baseline in CD4 was of marginal signifi cance (ITT 0.16 cells/mL 95%CI 0.0, 0.32). Mean change in HDL, LDL, total 
cholesterol triglycerides were signifi cantly greater in the ABC/3TC arm (p <0.01 for all), there was no difference in total 
cholesterol:HDL ratio (0.11 95%CI -0.16, 0.29). There was a greater proportion of SNAEs in the ABC/3TC arm (relative 
difference 3.8%, 95%CI 0.1, 7.6) primarily arising from the STEAL study.
Conclusions: In a switch study setting ABC/3TC based therapy was virologically non-inferior over 96 weeks to 
TDF/FTC based therapy. Lipid markers were generally elevated in the ABC/3TC arm.
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Formal analysis of comparison of the number of events by randomised 
arm was conducted only for individual SNAE events where greater 
than ten events were reported.
For binary endpoints, we used exact statistics to determine 
the relative differences in proportions (RD), and ANOVA based 
methods for differences between means. Difference was for ABC/3TC 
minus TDF/FTC. Data were summarised across trials using random 
effects meta-analysis methods to maintain the integrity of each 
trial. Heterogeneity was assessed using I2 [14]. In all comparisons 
two sided tests were used with <0.05 considered as significant. 
Sensitivity of findings regarding continuous outcomes was assessed 
by stratification of baseline use of PI and baseline use of ABC, TDF 
or other NRTI. Due to the small number of eligible studies, no 
formal analysis of publication bias was undertaken. All analyses were 
conducted using STATATM 10 using the metan function. 
Results
Study Characteristics
Eligibility criteria for BICOMBO and STEAL have been published 
elsewhere [12,13]. In both trials participants were required to 
have baseline exposure to two nucleoside reverse transcriptase 
inhibitors (NRTIS) and either a non-NRTI or protease inhibitor, and 
be virologicially suppressed (HIV RNA < 200 and <50 copies /mL 
plasma respectively).   In summary the main differences in eligibility 
criteria between trials were: STEAL alone required participants to 
be HLA-B*5701 negative or have had prior exposure to ABC and 
eGFR70mL/min/1.73m2;  BICOMBO participants were excluded 
if plasma creatinine was >2mg/dL.  Both trials required written 
informed consent prior to randomisation. Recruitment for BICOMBO 
and STEAL were exclusively from Spain and Australia respectively. 
Baseline Data
Baseline and follow-up characteristics, which were measured 
in both trials, by randomised arm are shown in (Table 1). Loss to 
follow-up differed between trials, and within BICOMBO by study 
arm, with the BICOMBO TDF/FTC having the greatest loss to follow 
up (16%). Within each trial all other baseline characteristics were 
balanced across randomized arms. BICOMBO in comparison to STEAL 
had a lower proportion of participants who were male (77% vs 98%), 
exposed to ABC at baseline (9% vs 20%) and with HIV transmission via 
male homosexual contact (31% vs 89%) and a higher proportion who 
had prior AIDS (38% vs 16%). Biochemical parameters were similar 
between trials except eGRF was lower in BICOMBO (mean 75 vs 98 
ml/min/1.73m2)
Outcomes
In terms of virological and immunological findings, results were 
similar between trials (Figure 1 and Figure 2). Pooled analysis showed 
no difference between arms for virologic failure, regardless of 
whether analysis was by ITTM=F (relative difference 0.7 %, 95%CI-3.4, 
4.8), ITTS=F (relative difference 2.8%, 95%CI -2.6, 8.2), or PP (relative 
difference 0.8%, 95%CI -0.8, 2.4). There were no differences between 
randomised arms in change from baseline to week 96 in log10 HIV 
RNA copies/mL (SMD ITT 0.08 95%CI -0.08, 0.23; PP -0.02 95%CI -0.22, 
0.18). Change in CD4+Tcell count/L was significantly greater in 
the ABC/3TC arm in the ITT population but there was no significant 
difference in the PP population (SMD, ITT 0.16 95%CI, 0.00, 0.32; PP 
0.15 95%CI -0.03, 0.34) (Table 2). There was no significant difference 
in cessation of randomised therapy by treatment arm (relative 
difference 1.5%, 95%CI -3.9, 6.8).
The following lipid parameters (Figure 2)  were significantly 
higher in the ABC+3TC arm compared to the TDF+FTC arm in 
pooled analysis: triglycerides mmol/L (SMD 0.25 95%CI 0.08, 0.42); 
total cholesterol (SMD  0.62 95%CI 0.45, 0.80);HDL cholesterol (SMD 
0.30 95%CI 0.13, 0.48); LDL cholesterol (SMD 0.33 95%CI 0.14, 0.51). 
There were no significant difference in total cholesterol: HDL ratio 
(SMD 0.11 95%CI -0.06, 0.29).
There were no significant differences between arms in pooled 
analysis of weight (SMD 0.02 95%CI -0.45, 0.49), kidney function 
(SMD CrCl -0.08 95%CI-0.51, 0.36; GFR -0.01 95%CI-0.18, 0.16) nor 
liver function (SMD ALT -0.06 95%CI -0.47, 0.34; AST 0.00 95%CI -0.40, 
0.40) (Figure 2). These variables showed the greatest between trial 
heterogeneity, significantly so for aminotransferases (ALT I2=82%, 
p=0.018; AST I2=80.7% p=0.023). There were no clinically relevant 
BICOMBO STEAL
ABC/3TC TDF/FTC ABC/3TC TDF/FTC
n=167 n=166 n=178 n=179
Lost to follow up (%) 13 7.8 27 16.3 4 2.2 2 1.1
Baseline ABC (%) 12 7.2 18 10.8 36 20.2 37 20.7
Baseline TDF (%) 44 26.3 56 33.7 54 30.3 53 29.6
Baseline PI (%) 17 10.2 16 9.6 42 23.6 41 22.9
NRTI exposure [years(sd)] 4.4 2.9 4.1 2.9 5.7 3.4 5.9 3.8
Male (%) 130 77.8 127 76.5 176 98.9 173 96.6
Male homosexual transmission (%)* 55 35.0 51 32.1 157 88.2 159 88.8
Prior AIDS (%) 63 37.7 65 39.2 31 17.4 28 15.6
 Age [years(sd) 43 9 45 10 46 9 44 8
 CD4 count [cells/mm3(sd)] 533 292 554 299 627 306 599 257
Creatinine clearance [ml/min(sd)] 105 25.2 100 27 112 26.3 114 27.4
eGFR [ml/min/1.73m2 (sd)] 75.7 31.6 73.3 34 98.2 22.4 98.4 17
Triglycerided[mmol/L(sd)] 1.8 1.1 2 1.4 2.2 2.7 2.3 3
Total:HDL ratio 4 1.3 4.2 1.4 4.3 1.6 4.4 1.4
Total cholesterol[mmol/L(sd)] 5.2 1 5.4 1 5.2 1 5.4 1.3
HDL cholesterol[mmol/L(sd)] 1.4 0.4 1.4 0.5 1.3 0.4 1.3 0.4
LDL cholesterol[mmol/L(sd)] 3.1 0.8 3.1 0.9 3.1 0.9 3.1 0.9
ALT > ULN** 48 31.4 54 34.8 40 22.4 36 20.2
AST >ULN† 23 15.6 36 24.8 36 20.1 31 17.4
*Transmisssion information was available only for 157 and 159 participants in ABC/3TC and TDF/FTC  BICOMBO arms respectively
**ALT data available only for 153, 155, 178,178 participants on ABC/3TC and TDF/FTC in BICOMBO and STEAL respectively
†AST data available only for 147 and 145 participants on ABC/3TC and TDF/FTC in BICOMBO
ALT-alanine aminotransferase
AST-aspartate aminotransferase
ULN- upper limit of normal
Table I: Baseline characteristics by trial and randomised arm.
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differences in outcomes after stratification for baseline PI or NRTI use 
(data not shown).
A total of 37 SNAEs were reported across both trials (Table 2). 
A significantly greater proportion of SNAEs were reported in the 
ABC+3TC arm (relative difference 3.8% 95%CI 0.1, 7.6 p=0.044; 
I2=19.5% p heterogeneity=0.265). Across trials the most frequently 
reported events, of all SNAEs, were cancer (17/37, 46%) and 
cardiovascular disease (CVD) (12/37, 32%). There were no significant 
differences between arms in pooled data for either of these events 
(relative difference 1.5% 95%CI -0.8, 3.7 p=0.197 and RD 2.1 95%CI 
-1.6, 5.7 p=0.267 respectively). The following cancers were reported: 
four Hodgkin’s lymphoma, three cervical, two lung and one of kidney, 
prostate, liver, larynx, vulvar, testicular, an unknown primary and 
one metastatic melanoma. The following CVD events were reported: 
6 myocardial infarctions, two peripheral arterial disease [one with 
angioplasty], one coronary artery by-pass surgery, two ischaemic 
stroke, and one deep venous thrombosis. The majority of CVD 
events were reported in the STEAL ABC+3TC arm (8/12, 67%), and 
variation in relative difference that was attributable to between 
trial heterogeneity was 73% (I2) which was of borderline significance 
(p=0.055).
 
NOTE: Weights are from random effects analysis
ITT
(I-squared = 5.1%, p = 0.305)





































Figure 1: Difference between treatment arms in proportion (RD) with virologic failure by method of analysis.
RD Difference in proportions, (ABC/3TC) minus (TDF/FTC)
ITT Intention to treat missing=failure
ITS Intention to treat missing/switch=failure
PP Per protocol
BICOMBO STEAL
ABC/3TC TDF/FTC ABC/3TC TDF/FTC
n=167 n=166 n=178 n=179
n % n % n % n %
Deaths 0 - 2 1.2 2 1.1 2 1.1
AIDS events 1 0.6 0 - 0 - 0 -
Serious non-AIDS
Cardio vascular 2 1.2 1 0.6 8 4.5 1 0.6
Study RD [%(95% CI] 0.6 (-1.4,2.6) 3.9 (0.7, 7.1)
RD[% (95%CI)] 2.1 (-1.6, 5.7)p=0.267, heterogeneity  I272.9 p=0.055
Cancer 6 3.6 4 2.4 5 2.8 2 1.1
Study RD [%(95% CI] 1.2(-2.5, 4.8) 1.7 (-1.2, 4.5)
RD[% (95%CI)] 1.5 (-0.8, 3.7) p=0.197, heterogeneity I20.0% p=0.834
Fracture 3 1.8 2 1.2 0 0.0 1 0.6
Renal disease 0 0.0 1 0.6 0 0.0 0 0.0
Liver disease 0 0.0 0 0.0 1 0.6 0 0.0
Total 11 6.6 8 4.8 14 7.9 4 2.2
Study RD [% (95%CI)] 1.8 (-3.2, 6.7) 5.6 (1.1, 10.1)
RD[% (95%CI)] 3.8 (0.1, 7.6) p=0.044, heterogeneity I2=19.5% p=0.265
*Only grade 3/4 adverse events that resulted in treatment cessation
RD= Difference in proportions, (ABC+3TC) minus (TDF+FTC)
Table 2: Serious non -AIDS events by randomised arm and trial.
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There were six deaths in the trials, two in BICOMBO on TDF+FTC 
(one acute myocardial infarction, one cerebral hemorrhage) and four in 
STEAL (all cancers). There was one new AIDS event (Cryptosporidium 
parvum enteritis), which occurred in the in ABC+3TC arm of 
BICOMBO. 
Discussion
This meta-analysis showed an overall consistency in efficacy 
in response to randomization to ABC/3TC or TDF/FTC across the 
BICOMBO and STEAL trials. Over 96 weeks, ABC/3TC was found to 
be non-inferior to TDF/FTC in terms of ability to maintain virologic 
suppression and with regards to CD4+ T-cell response. ABC/3TC 
was associated with greater increases in lipid levels and a greater 
frequency of SNAEs. The greatest imbalance in SNAEs was for CVD 
events, the majority of which were reported in the STEAL study.
Greater lipid increases in the ABC/3TC were evident across a range 
of measures including total cholesterol, triglycerides, LDL. These 
findings may lend support to potential cardiac risk following exposure 
to ABC, however HDL was significantly greater in the ABC/3TC arm 
and there was no significant difference in total cholesterol:HDL ratio.
Figure 2: Standardised mean difference (SMD) between randomised arms in change from baseline to week 96 in the per protocol population.
SMD= Difference in mean change from baseline, (ABC/3TC) minus (TDF/FTC)
Weights are from random effects analysis: % weight range BIOCOMBO 40.04-48.70; STEAL 51.30-58.78
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 Our findings regarding SNAEs are of interest however should be 
interpreted cautiously. Firstly, the higher proportion of SNAEs in the 
ABC arm was of borderline significance (p 0.044) and appears driven 
by the distribution of CVD events in STEAL. The pooled result for CVD 
was not statistically significant and between study heterogeneity 
for this event approached statistical significance (p=0.055). The 
numbers of CVD events in BICOMBO were much lower than in STEAL 
(3 vs 9). Secondly, underlying differences in cardiac risk in the Spanish 
and Australian populations may explain some of the difference in 
this finding between BICOMBO and STEAL.  The STEAL population 
consisted of more men than the BICOMBO population, an important 
risk factor for CVD.[15] Thirdly, bias in assignment of SNAEs in the 
BICOMBO study cannot be discounted as endpoints were identified 
by retrospectives case record review. Fourthly, the higher rate of 
loss to follow up in BICOMBO may have resulted in the omission of 
some longer term outcomes (such as CVD). Finally, while our findings 
lend some support to the association of ABC use and myocardial 
infarction observed in observational studies,[4,5,16] our definition 
of CVD includes other cardiac events, such as stroke and peripheral 
vascular disease, which may have different underling aetiology and 
have resulted in misclassification error.
Across the studies there was no evidence of difference by 
randomised arm in renal function as determined by change in GFR, 
creatinine clearance or serious renal events.  Liver function (as 
assessed by ALT and AST results) similarly showed no difference 
overall, however there was significant heterogeneity between trials, 
perhaps indicating differing underlying risk for this variable. Baseline 
ALT and AST were higher in BICOMBO than STEAL. Hepatitis B and 
C co-infection, which contribute to ALT and AST elevation, were not 
ascertained in STEAL. However, the estimated prevalence of these co-
infections in the Spanish HIV population (37% and 20-50% respectively) 
is greater than in the Australian (6% and 13% respectively). [17-19]
The primary limitation of BICOMBO and STEAL, and therefore 
this combined analysis, was the inclusion of participants who were 
not naïve to TDF and ABC. However stratification by baseline NRTI 
showed no significant interaction between baseline exposure to ABC/
TDF and randomised treatment for any outcome.  Further, as week 96 
analysis was not protocol mandated in BICOMBO, no BICOMBO DEXA 
data are available for this time point, as such no combined analysis 
of body composition nor bone mineral density could be undertaken. 
Further, it is unknown how the higher rate of loss to follow up in 
BICOMBO may have affected trial outcomes.
The primary strength of this analysis is that raw data were 
available for both trials. Therefore we were able to ensure that all 
endpoints were analysed in the same way prior to pooling. Another 
strength is that by encompassing both the BICOMBO and STEAL 
study populations, the findings are generalisable to a more diverse 
population. This was possible because there was very little evidence 
of heterogeneity for the majority of endpoints across the trial, 
indicating that the response to ABC/3TC and TDF/FTC is not trial 
specific.
In summary, our data demonstrate that over 96 weeks, switching 
to ABC/3TC is virologically non-inferior to switching to TDF/FTC in 
ART experienced virologically suppressed HIV infected populations. 
SNAEs and some lipids were however elevated in the ABC/3TC arm. 
Our  analysis lends support to the suggestion that SNAEs should be 
routinely collected in switch trials.
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